A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)
Indication: Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Gastric Cancer, Gastric Cancer, Gastric Cancer, Gastric Cancer, Gastric Cancer, Gastric Cancer, Gastric Cancer, Gastric Cancer, Gastric Cancer, Gastric Cancer, Gastric Cancer, Gastric Cancer, Gastric Cancer, Gastric Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Head and Neck Cancer, Liver Cancer, Liver Cancer, Liver Cancer, Liver Cancer, Liver Cancer, Liver Cancer, Liver Cancer, Liver Cancer, Liver Cancer, Liver Cancer, Liver Cancer, Liver Cancer, Liver Cancer, Liver Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Pancreatic Cancer, Pancreatic Cancer, Pancreatic Cancer, Pancreatic Cancer, Pancreatic Cancer, Pancreatic Cancer, Pancreatic Cancer, Pancreatic Cancer, Pancreatic Cancer, Pancreatic Cancer, Pancreatic Cancer, Pancreatic Cancer, Pancreatic Cancer, Pancreatic Cancer
Trial Number: 06330064
Trial Status: OPEN